Journey Medical CORP (DERM) — SEC Filings

Q: What are the key financial highlights for Journey Medical CORP?

Key financial highlights for Journey Medical CORP are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Journey Medical CORP?

Key executives at Journey Medical CORP are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Journey Medical CORP stock?

Risk factors for Journey Medical CORP (DERM) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Journey Medical CORP?

Forward-looking statements and predictions from Journey Medical CORP are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Journey Medical CORP. Recent 10-Q filing on Nov 12, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Journey Medical CORP on SEC EDGAR

Overview

Journey Medical CORP (DERM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 12, 2025: Journey Medical Corp (DERM) reported a net loss of $10.184 million for the nine months ended September 30, 2025, an improvement from the $16.193 million net loss in the prior-year period. Total revenue increased to $45.779 million for the nine months ended September 30, 2025, up from $42.514 million

Sentiment Summary

Across 31 filings, the sentiment breakdown is: 1 bullish, 28 neutral, 2 mixed. The dominant filing sentiment for Journey Medical CORP is neutral.

Filing Type Overview

Journey Medical CORP (DERM) has filed 6 10-Q, 20 8-K, 2 DEF 14A, 2 10-K, 1 SC 13G with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (31)

Journey Medical Narrows Losses, Boosts Revenue Amid ATM Offering — 10-Q · Nov 12, 2025 Risk: high
Journey Medical Corp (DERM) reported a net loss of $10.184 million for the nine months ended September 30, 2025, an improvement from the $16.193 million net los
Journey Medical Corp Enters Material Definitive Agreement — 8-K · Sep 26, 2025 Risk: medium
On September 25, 2025, Journey Medical Corporation entered into a material definitive agreement related to a direct financial obligation. The company, incorpora
Journey Medical Corp: Material Agreements and Terminations Announced — 8-K · Aug 28, 2025 Risk: medium
Journey Medical Corporation announced on August 28, 2025, the entry into a material definitive agreement and the termination of a material definitive agreement.
Journey Medical Corp Files 8-K on Financials — 8-K · Aug 12, 2025 Risk: low
Journey Medical Corporation filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition. The filing includes financial state
Journey Medical Narrows Losses, Emrosi Approval Boosts Outlook — 10-Q · Aug 12, 2025 Risk: high
Journey Medical Corp (DERM) reported a net loss of $7.87 million for the six-month period ended June 30, 2025, an improvement from the $13.80 million net loss i
Journey Medical Corp Files 8-K — 8-K · Jul 14, 2025 Risk: low
On July 14, 2025, Journey Medical Corporation filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no
Journey Medical Corp Files 8-K with Corporate Updates — 8-K · Jun 26, 2025 Risk: low
Journey Medical Corporation filed an 8-K on June 26, 2025, reporting events as of June 24, 2025. The filing indicates changes related to amendments to articles
Journey Medical Corp Files 8-K — 8-K · Jun 24, 2025 Risk: low
On June 24, 2025, Journey Medical Corporation filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specifi
Journey Medical Corp. Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: low
Journey Medical Corp. filed its 10-Q for the period ending March 31, 2025. The filing details financial information for the first quarter of 2025, including com
Journey Medical Corp Files 8-K on Financials — 8-K · May 14, 2025 Risk: low
Journey Medical Corporation filed an 8-K on May 14, 2025, reporting on its results of operations and financial condition, as well as filing financial statements
Journey Medical Corp Files Definitive Proxy Statement — DEF 14A · Apr 29, 2025 Risk: low
Journey Medical Corporation filed a Definitive Proxy Statement (DEF 14A) on April 29, 2025, for its annual meeting on June 24, 2025. The company, based in Scott
Journey Medical Corp Files 8-K on Director/Officer Changes — 8-K · Apr 3, 2025 Risk: low
Journey Medical Corporation filed an 8-K on April 3, 2025, reporting events as of April 1, 2025. The filing pertains to the departure and election of directors,
Journey Medical Corp. Files 2024 10-K — 10-K · Mar 27, 2025 Risk: low
Journey Medical Corp. filed its 2024 10-K on March 27, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, inco
Journey Medical Corp Files 8-K on Financials — 8-K · Mar 26, 2025 Risk: low
Journey Medical Corporation filed an 8-K on March 26, 2025, reporting on its results of operations and financial condition, and filing financial statements and
Journey Medical Corp Files 8-K — 8-K · Mar 24, 2025 Risk: low
Journey Medical Corporation filed an 8-K on March 24, 2025, reporting other events and financial statements. The filing details the company's principal executiv
8-K Filing — 8-K · Feb 5, 2025
SC 13G Filing — SC 13G · Nov 29, 2024
Journey Medical Corp Files 8-K on Financials — 8-K · Nov 12, 2024 Risk: low
Journey Medical Corporation filed an 8-K on November 12, 2024, reporting on its results of operations and financial condition, and including financial statement
Journey Medical Corp. Q3 2024 10-Q Filed — 10-Q · Nov 12, 2024 Risk: low
Journey Medical Corp. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the third quarter of 2024, detailing c
Journey Medical Corp Files 8-K — 8-K · Nov 4, 2024 Risk: low
Journey Medical Corporation filed an 8-K on November 4, 2024, to report on its results of operations and financial condition, other events, and financial statem
Journey Medical Corp. Files Q2 2024 10-Q — 10-Q · Aug 13, 2024 Risk: low
Journey Medical Corp. filed a 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second quarter.
Journey Medical Corp Files 8-K on Operations — 8-K · Aug 12, 2024 Risk: low
Journey Medical Corporation filed an 8-K on August 12, 2024, to report on its results of operations and financial condition, as well as to file financial statem
Journey Medical Corp: Board Changes & Financial Obligations — 8-K · Jul 12, 2024 Risk: medium
On July 9, 2024, Journey Medical Corporation entered into a material definitive agreement related to a direct financial obligation. The company also reported th
Journey Medical Corp Files 8-K on Director Changes and Shareholder Votes — 8-K · Jun 25, 2024 Risk: low
Journey Medical Corporation filed an 8-K on June 25, 2024, reporting on the departure of directors, election of new directors, and compensatory arrangements. Th
Journey Medical Corp Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 14, 2024 Risk: medium
Journey Medical Corp (DERM) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Journey Medical Corp filed a 10-Q for the period ending March 31, 2024
Journey Medical Corp Files 8-K for Financial Reporting — 8-K · May 13, 2024 Risk: low
Journey Medical Corporation filed an 8-K on May 13, 2024, to report on its results of operations and financial condition, as well as to file financial statement
Journey Medical Corp. CFO Departs, New Directors Appointed — 8-K · May 1, 2024 Risk: medium
Journey Medical Corporation announced on April 26, 2024, the departure of its Chief Financial Officer, Michael Miller. The company has appointed David R. Miller
Journey Medical Corp. Announces Annual Meeting of Stockholders on June 25, 2024 — DEF 14A · Apr 29, 2024 Risk: low
Journey Medical Corp (DERM) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Annual Meeting of Stockholders to be held virtually on June 25, 20
Journey Medical Corp. Files 2023 Annual Report on Form 10-K — 10-K · Mar 29, 2024 Risk:
Journey Medical Corp (DERM) filed a Annual Report (10-K) with the SEC on March 29, 2024. Journey Medical Corp. filed its 2023 Form 10-K on March 29, 2024, repor
Journey Medical Corp Files 8-K — 8-K · Mar 21, 2024 Risk: low
Journey Medical Corporation filed an 8-K on March 21, 2024, to report on its results of operations and financial condition, as well as to file financial stateme
Journey Medical Secures New $20M Credit Facility — 8-K · Jan 2, 2024
Journey Medical Corp (DERM) entered into a significant financing agreement on December 27, 2023, securing a new credit facility for up to $20 million. This faci

Risk Profile

Risk Assessment: Of DERM's 27 recent filings, 2 were flagged as high-risk, 5 as medium-risk, and 20 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Journey Medical CORP's most recent 10-Q filing (Nov 12, 2025):

Revenue: $45,779,000
Net Income: -$10,184,000
EPS: N/A
Debt-to-Equity: 2.29
Cash Position: $24,948,000
Operating Margin: -16.7%
Total Assets: $85,191,000
Total Debt: $59,293,000

Key Executives

Chief Executive Officer
Michael Miller
David R. Miller
David M. R. Miller
Robert L. Johnson

Industry Context

Journey Medical Corp operates in the competitive dermatology and pharmaceutical market. The industry is characterized by significant R&D investment, regulatory hurdles, and the need for effective marketing to gain market share. Trends include the development of novel treatments and the increasing demand for aesthetic and therapeutic dermatological solutions.

Top Tags

financial-reporting (7) · 8-k (5) · financials (5) · 10-Q (4) · Dermatology (3) · regulatory-filing (3) · corporate-governance (3) · sec-filing (3) · Pharmaceuticals (2) · Net Loss (2)

Key Numbers

Net Loss: $10.184M — for the nine months ended September 30, 2025, an improvement from $16.193M in 2024
Total Revenue: $45.779M — for the nine months ended September 30, 2025, up 7.7% from $42.514M in 2024
Cash and Cash Equivalents: $24.948M — as of September 30, 2025, up from $20.305M at December 31, 2024
Research and Development Expenses: $326K — for the nine months ended September 30, 2025, a significant decrease from $9.639M in 2024
Proceeds from ATM Offering: $10.939M — net of issuance costs, for the nine months ended September 30, 2025
Credit Facility Maturity Date: June 27, 2028 — extended from December 27, 2027
Revenue Threshold for Interest-Only Period: $60.0M — lowered from $70.0M for the Credit Facility
Working Capital: $16.7M — as of September 30, 2025, up from $13.0M at December 31, 2024
Commission File Number: 001-41063 — Identifies the company's SEC filing history.
IRS Employer Identification No.: 47-1879539 — Company's tax identification number.
Product Revenue, Net (H1 2025): $28.15M — Increased from $27.89M in H1 2024, a 0.9% increase.
Net Loss (H1 2025): $7.87M — Improved from $13.80M in H1 2024, a 43% reduction.
Research and Development (H1 2025): $39K — Significantly decreased from $8.80M in H1 2024, a 99.6% reduction.
Selling, General and Administrative (H1 2025): $22.45M — Increased from $18.75M in H1 2024, a 19.7% increase.
Cash and Cash Equivalents (June 30, 2025): $20.29M — Stable compared to $20.31M at December 31, 2024.

Related Companies

FBIO · JMEI · JRNRY

Frequently Asked Questions

What are the latest SEC filings for Journey Medical CORP (DERM)?

Journey Medical CORP has 31 recent SEC filings from Jan 2024 to Nov 2025, including 20 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of DERM filings?

Across 31 filings, the sentiment breakdown is: 1 bullish, 28 neutral, 2 mixed. The dominant sentiment is neutral.

Where can I find Journey Medical CORP SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Journey Medical CORP (DERM) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Journey Medical CORP?

Key financial highlights from Journey Medical CORP's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for DERM?

The investment thesis for DERM includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Journey Medical CORP?

Key executives identified across Journey Medical CORP's filings include Chief Executive Officer, Michael Miller, David R. Miller, David M. R. Miller, Robert L. Johnson.

What are the main risk factors for Journey Medical CORP stock?

Of DERM's 27 assessed filings, 2 were flagged high-risk, 5 medium-risk, and 20 low-risk.

What are recent predictions and forward guidance from Journey Medical CORP?

Forward guidance and predictions for Journey Medical CORP are extracted from SEC filings as they are enriched.